KalVista Pharmaceuticals (KALV) Non-Current Assets (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Non-Current Assets data on file, last reported at $9.6 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Assets rose 12.2% year-over-year to $9.6 million; the trailing twelve-month figure through Jul 2025 stood at $36.1 million (down 5.72% YoY), and the FY2025 full-year result was $9.1 million, down 6.53% from the prior year.
• Non-Current Assets grew to $9.6 million in Q3 2025, from $9.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $11.9 million in Q3 2022 to a low of $3.7 million in Q1 2021.
• A 5-year average of $9.6 million and a median of $9.7 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 186.01% in 2022 and retreated 18.36% in 2024, its largest moves.
• Tracing KALV's Non-Current Assets over 5 years: stood at $9.3 million in 2021, then climbed by 24.54% to $11.6 million in 2022, then dropped by 12.78% to $10.1 million in 2023, then retreated by 12.82% to $8.8 million in 2024, then grew by 8.74% to $9.6 million in 2025.
• Business Quant data shows KALV's Non-Current Assets at $9.6 million in Q3 2025, $9.1 million in Q2 2025, and $8.8 million in Q4 2024.